SCHEMBL4201158

SCHEMBL4201158

O=c1ccn(C2C[C@H](O)[C@@H](C(O)Br)O2)c(=O)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DUT P33316 4/20 0.50
SLC28A1 O00337 1/20 0.42
SLC28A2 O43868 1/20 0.42
SLC29A1 Q99808 1/20 0.42
SLC28A3 Q9HAS3 1/20 0.42
P2RY2 P41231 6/20 0.38
P2RY6 Q15077 2/20 0.38
P2RY4 P51582 3/20 0.38
TK1 P04183 3/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41471 1.00 DUT (0.50) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL3340603 1.00 DUT (0.50) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL2557435 1.00 DUT (0.50) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL6034458 0.91 DUT (0.53) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL28745696 0.88 DUT (0.51) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL249821 0.88 DUT (0.51) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL10765602 0.88 DUT (0.51) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL2056622 0.88 DUT (0.51) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL15771583 0.88 DUT (0.51) DUTSLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL414704 0.88 DUT (0.51) DUTSLC28A1SLC28A2SLC29A1SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102307868-B Indole derivatives as anticarcinogen 詹森药业有限公司 2016-06-22 CN disclosed
CN-105229002-A BET protein inhibiting dihydropyridopyrazinones Bayer Pharma AG 2016-01-06 CN disclosed
CN-105061598-A anti-IL-1R 1 binding members MEDIMMUNE LTD 2015-11-18 CN disclosed
CN-104884472-A Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof ABBVIE INC 2015-09-02 CN disclosed
CN-102307901-B anti-IL-1R 1 binding members MEDIMMUNE, LLC (GB) 2015-08-19 CN disclosed
CN-101970424-B Indolylpyridone derivatives with checkpoint kinase 1 inhibitory activity VERNALIS R&D LTD 2013-06-12 CN disclosed
CN-102459608-A Combined engineering BOEHRINGER INGELHEIM INT 2012-05-16 CN disclosed
CN-102414320-A Improved cell lines with reduced NOCR expression and uses thereof BOEHRINGER INGELHEIM INT 2012-04-11 CN disclosed
CN-102307901-A anti-IL-1R 1 binding members MEDIMMUNE LTD 2012-01-04 CN disclosed
CN-102307868-A Indole derivatives as anticancer agents JANSSEN PHARMACEUTICA NV 2012-01-04 CN disclosed
CN-101945867-A Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors AMGEN INC 2011-01-12 CN disclosed
CN-1976906-B Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV 2010-09-01 CN disclosed
US-7608402-B2 DNA methylation specific signal amplification LI WEIWEI 2009-10-27 US disclosed
US-20090181373-A1 DNA methylation specific signal amplification LI WEIWEI 2009-07-16 US disclosed
CN-101394844-A Methoxypolyethylene glycol thioester chelate and uses thereof EASTERN VIRGINIA MED SCHOOL (US) 2009-03-25 CN disclosed
CN-101115727-A Compounds for inhibition of CHK1 ICOS CORP (US) 2008-01-30 CN disclosed
CN-1976906-A Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV (BE) 2007-06-06 CN disclosed
CN-1367693-A Pharmaceutical compositions containing poly(ADP-ribose) glycohydrolase inhibitors and method of using the same GUILFORD PHARM INC (US) 2002-09-04 CN disclosed
CN-1278797-A Oxo-substituted compouns, process of making, and compositions and methods for inhibiting parp activity GUILFORD PHARMACETICALS INC (US) 2001-01-03 CN disclosed
CN-1277613-A Poly (ADP-ribose) polymerase ('PARP') inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage GUILFORD PHARM INC (US) 2000-12-20 CN disclosed